Leukemia Inhibitory Factor and Interleukin-11 Promote Maturation of Murine and Human Megakaryocytes in Vitro
Overview
Physiology
Authors
Affiliations
The growth-promoting activities of optimally stimulating concentrations of leukemia inhibitory factor (LIF) and interleukin-11 (IL-11), a stromal cell-derived cytokine, on megakaryocytes in liquid marrow cultures were compared to interleukin-6 (IL-6), a known megakaryocytes maturation factor. Maximally stimulating concentrations of LIF (25 ng/ml), IL-11 (10 ng/ml), or IL-6 alone (10 ng/ml) promoted an 81, 157, and 153% increase, respectively, in acetylcholinesterase (AchE) activity in murine serum-free cultures compared with controls (n = 5). In combination with 25 U/ml murine interleukin-3 (IL-3), LIF, IL-6, and IL-11 showed increases, respectively, of 35%, 49%, and 174% in AchE activity compared with IL-3 alone (n = 4). Flow cytometric analysis of 4-day-old cultures showed that LIF alone had minimal effect on megakaryocytic ploidy, whereas IL-11 and IL-6 alone markedly augmented high ploidy cells. Enumeration of cells stained for AchE showed that IL-11 increased the numbers of Mks in comparison to LIF, IL-6 or controls by up to 59%. Moreover, a twofold increment in Mk number was noted when IL-11 was used in combination with IL-3 (compared with either IL-3 alone of IL-3+IL-6). Flow cytometric ploidy analysis of 8-day-old human liquid marrow cultures showed that either LIF, IL-11, or IL-6 alone markedly augmented the percentage of 32N cells compared with cultures containing only human IL-3. The data suggest that LIF and IL-11 promote murine and human Mk maturation in vitro, although the effect of IL-11 exceeds that of LIF in mice. Despite the comparable influence of IL-11 and IL-6 on Mk ploidy, IL-11 has the additional characteristic of enhancing the number of Mks, particularly in combination with IL-3.
Megakaryocyte Diversity in Ontogeny, Functions and Cell-Cell Interactions.
Khatib-Massalha E, Mendez-Ferrer S Front Oncol. 2022; 12:840044.
PMID: 35186768 PMC: 8854253. DOI: 10.3389/fonc.2022.840044.
Kotyla P, Engelmann M, Giemza-Stoklosa J, Wnuk B, Islam M Int J Mol Sci. 2021; 22(5).
PMID: 33671049 PMC: 7957632. DOI: 10.3390/ijms22052449.
Oylumlu M, Oylumlu M, Arslan B, Polat N, Ozbek M, Demir M Postepy Kardiol Interwencyjnej. 2020; 16(2):170-176.
PMID: 32636901 PMC: 7333190. DOI: 10.5114/aic.2020.95859.
Lewis B, Leontyev D, Neschadim A, Blacquiere M, Branch D Clin Exp Immunol. 2018; 193(3):293-301.
PMID: 29704458 PMC: 6150254. DOI: 10.1111/cei.13144.
Li W, Liu Q, Tang Y Sci Rep. 2017; 7:40426.
PMID: 28071752 PMC: 5223131. DOI: 10.1038/srep40426.